Related Experiment Video
Updated: Jun 15, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
Folding and membrane insertion of amyloid-beta (25-35) peptide and its mutants: implications for aggregation and
Hui-Hsu Gavin Tsai1, Jian-Bin Lee, Sheng-Shiuan Tseng
1Department of Chemistry, National Central University, Jhong-Li City, Tao-Yuan County, Taiwan. hhtsai@cc.ncu.edu.tw
Abstract:
The mechanisms of interfacial folding and membrane insertion of the Alzheimer's amyloid-beta fragment Abeta(25-35) and its less toxic mutant, N27A-Abeta(25-35) and more toxic mutant, M35A-Abeta(25-35), are investigated using replica-exchange molecular dynamics in an implicit water-membrane environment. This study simulates the processes of interfacial folding and membrane insertion in a spontaneous fashion to identify their general mechanisms. Abeta(25-35) and N27A-Abeta(25-35) peptides share similar mechanisms: the peptides are first located in the membrane hydrophilic region where their C-terminal residues form helical structures. The peptides attempt to insert themselves into the membrane hydrophobic region using the C-terminal or central hydrophobic residues. A small portion of peptides can successfully enter the membrane's hydrophobic core, led by their C-terminal residues, through the formation of continuous helical structures. No detectable amount of M35A-Abeta(25-35) peptides appeared to enter the membrane's hydrophobic core. The three studied peptides share a similar helical structure for their C-terminal five residues, and these residues mainly buried within the membrane's hydrophobic region. In contrast, their N-terminal properties are markedly different. With respect to the Abeta(25-35), the N27A-Abeta(25-35) forms a more structured helix and is buried deeper within the membrane, which may result in a lower degree of aggregation and a lower neurotoxicity; in contrast, the less structured and more water-exposed M35A-Abeta(25-35) is prone to aggregation and has a higher neurotoxicity. Understanding the mechanisms of Abeta peptide interfacial folding and membrane insertion will provide new insights into the mechanisms of neurodegradation and may give structure-based clues for rational drug design preventing amyloid associated diseases.
Insights
Alzheimer's amyloid-beta fragment (Abeta) peptides interact with cell membranes. Less toxic mutants fold and insert into membranes differently than more toxic ones, offering insights into neurodegeneration mechanisms.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Alzheimer's disease is linked to amyloid-beta (Abeta) peptide aggregation and neurotoxicity.
- Understanding Abeta peptide interactions with cell membranes is crucial for elucidating disease mechanisms.
Purpose of the Study:
- To investigate the interfacial folding and membrane insertion mechanisms of Alzheimer's amyloid-beta fragment (Abeta(25-35)) and its mutants.
- To compare the behavior of less toxic (N27A-Abeta(25-35)) and more toxic (M35A-Abeta(25-35)) mutants.
Main Methods:
- Replica-exchange molecular dynamics simulations were employed.
- Simulations were conducted in an implicit water-membrane environment to observe spontaneous folding and insertion.
Main Results:
- Abeta(25-35) and N27A-Abeta(25-35) peptides exhibit similar mechanisms, forming C-terminal helical structures in the hydrophilic region before attempting insertion.
- While some Abeta(25-35) and N27A-Abeta(25-35) peptides successfully insert into the hydrophobic core via helical structures, M35A-Abeta(25-35) showed no detectable insertion.
- N-terminal differences were observed: N27A-Abeta(25-35) formed a more structured helix buried deeper, potentially reducing aggregation and neurotoxicity, unlike the more aggregation-prone M35A-Abeta(25-35).
Conclusions:
- The study elucidates distinct interfacial folding and membrane insertion mechanisms for different Abeta(25-35) variants.
- Differences in N-terminal structures and membrane interactions correlate with varying aggregation propensity and neurotoxicity.
- Findings provide insights into neurodegeneration and potential structure-based drug design strategies for amyloid diseases.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Folding
Protein Folding
Molecular Chaperones and Protein Folding
The...

